AMRX: Amneal Pharmaceuticals Inc P/S Multiple

Symbol and logo of brand Amneal Pharmaceuticals, Inc. (AMRX)

Amneal Pharmaceuticals focuses on the production of biosimilars and Parkinson's disease therapies to drive profit growth. Business scalability relies on massive FDA-approved plant capacities that reduce production costs. Cost optimization is achieved through flexible outsourcing of clinical trials. On GURU.Markets, the change in the price-to-sales ratio demonstrates the market valuation of the asset, where the current level of the metric is 2.30.

AMRX Amneal Pharmaceuticals, Inc.: Price-to-Revenue Ratio in the range 07/04/2022 - 11/16/2026

Analytical breakdowns for Amneal Corp (AMRX)

- share price and consensus valuation forecast:
Fundamental company analysis:Amneal Pharmaceuticals Inc AMRX
Mass-produced product of Amneal Pharmaceuticals Inc

To assess long-term overpayment risks for the investor, it is essential to analyze the P/S ratio—the relationship between market capitalization and annual revenue—which determines the cost of every dollar of sales for Amneal Pharmaceuticals (AMRX). The historical P/S level on the GURU.Markets platform reflects the balance between market expectations and the company's actual growth in the complex generics and biosimilars segment while maintaining high portfolio margins.

Who Amneal Pharmaceuticals competes with

HLN (Haleon) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue Inc KVUE|Verona Pharma Corp - Price-to-Revenue Ratio|MENS: Market Cap to Revenue|Price-to-Revenue Coefficient Ligand Pharmaceuticals LGND|Perrigo (PRGO) - Price-to-Revenue Ratio|ALVO (Alvotech S.A.) - Price-to-Revenue Ratio|Market Cap to Revenue LQDA|P/S Multiple Galapagos Corp|Price-to-Revenue Ratio ANI Pharma (ANIP)|P/S Multiple MannKind Corporation (MNKD)|Price-to-Revenue Ratio Amphastar Pharmaceuticals Inc AMPH|P/S Multiple Pacira PCRX|ARS Pharmaceuticals Inc - P/S Multiple|TBPH - P/S Multiple|AQST (Aquestive Therapeutics) - Market Cap to Revenue|scPharmaceuticals, Inc. (SCPH) - P/S Multiple|Market Cap to Revenue TECX|P/S Multiple Tonix Pharma|Market Cap to Revenue SXTC (SXT Pharmaceuticals)|EPRX: Price-to-Sales Ratio|BioHarvest Sciences - Market Cap to Revenue|EXOZ: Market Cap to Revenue Ratio|ORMP - Price-to-Revenue Ratio|ENTX: Price-to-Revenue Ratio|HYFT: P/S Multiple|Market Cap to Revenue ABVC BioPharma Inc|CPIX (Cumberland Corp) - P/S Multiple|P/S Multiple quantumbiopharma.com|P/S Multiple FGEN|Market Cap to Revenue Telomir Pharmaceuticals, Inc. TELO|P/S Multiple RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Price-to-Sales Ratio|RLYB: Market Cap to Revenue|lexariabioscience.com (LEXX) - Market Cap to Revenue|Pulmatrix Inc (PULM) - Price-to-Revenue Ratio|PTHL: Market Cap to Sales Volume|APM (Aptorum Group Ltd) - P/S Multiple|Lyra Therapeutics Inc (LYRA) - Price-to-Revenue Coefficient|P/S Multiple IBO|Market Cap to Sales Volume TNFA|cbdMD, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PRFX|Altamira Therapeutics Ltd. - P/S Multiple|LIPO: Price-to-Revenue Ratio|OPTN: P/S Multiple|Price-to-Sales Ratio PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - P/S Multiple|PTPI (Petros Pharmaceuticals Inc) - Market Cap to Sales Volume|P/S Multiple QLI|SLRN - Price to Sales|P/S Multiple TFFP (TFF Pharmaceuticals, Inc)